# US 11,439,701 B2 · Bovine respiratory disease vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,701 B2
- Document ID: US11439701B2
- Status: Granted
- Kind: B2
- Application number: 16/610,660
- Filed: 2018-04-27
- Published: 2021-11-04
- Granted: 2022-09-13
- Earliest claimed: 2017-05-05
- Assignees: Elanco US Inc.
- Applicants: Elanco US Inc
- Inventors: Lucas Huntimer; Thomas Halbur
- Web page: https://patentgrep.com/patent/US11439701B2

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 39/12: Viral antigens
- A61K 39/295: Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to vaccines for treating bovine respiratory disease. Such vaccines contain a combination of bovine influenza D virus and Mannheimia haemolytica antigens. An upper respiratory infection with an IDV leads to an increased potential for M. haemolytica pathology in the lungs. The vaccines may contain further antigens from other bovine respiratory pathogens.

## Claims

### Claim 1

An immunogenic composition comprising a bovine influenza D virus antigen and a Mannheimia haemolytica antigen.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the Mannheimia haemolytica antigen is selected from the group of an inactivated bacterium, an extract of outer membrane proteins, and a recombinant leukotoxin, and any combination thereof.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the bovine influenza D virus antigen is an inactivated virus.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the bovine influenza D virus antigen is a modified, live virus.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, wherein the modified, live bovine influenza D virus antigen is a modified, live virus modified by codon deoptimization.

### Claim 6 (depends on 4)

The immunogenic composition of claim 4, wherein the modified, live bovine influenza D virus antigen comprises at least one codon-deoptimized genomic segment having a cDNA sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.

### Claim 7

A vaccine for bovine respiratory disease comprising a bovine influenza D virus antigen and a Mannheimia haemolytica antigen, and a pharmaceutically acceptable excipient, stabilizer, solubilizer, or diluent, and optionally an adjuvant.

### Claim 8 (depends on 7)

The vaccine of claim 7, further comprising at least one antigen from an additional bovine pathogen.

### Claim 9 (depends on 8)

The vaccine of claim 8, wherein the additional bovine pathogen is selected from the group of bovine viral diarrhea virus (BVDV), bovine respiratory syncytia virus (BRSV), bovine herpesvirus (BHV), parainfluenza virus 3 (PB), Pasteurella multocida, Leptospira species, and Histophilus somni, and any combination thereof.

### Claim 10 (depends on 1)

A method of treating or preventing bovine respiratory disease, comprising administering to a bovine the immunogenic composition of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the administering is done orally, intranasally, intratracheally, or by injection.

### Claim 12 (depends on 7)

A method of treating or preventing bovine respiratory disease, comprising administering to a bovine the vaccine of claim 7.

### Claim 13 (depends on 12)

The method of claim 12, wherein the administering is done orally, intranasally, intratracheally, or by injection.